ClinicalTrials.gg
CompletedNCT01653262Updated Jul 11, 2018Results posted

Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)

A Phase 3 interventional study of Brivaracetam in Epilepsy, sponsored by UCB Pharma SA. Completed at 12 sites in 5 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2018-07-11.

Sponsored by UCB Pharma SA (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
25th of 34
29 · median 94
Started
2012
with 1 other
Phase 3
21 of 34
1 open now
Registered
19th of 34
by date
Lead sponsor
5 of 34
UCB Pharma SA

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 25th largest by enrollment, is one of 2 that started in 2012, is one of 21 in phase 3, and was the 19th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

Trial N01395 is to evaluate the reduction of nonpsychotic behavioral side effects in subjects with Epilepsy who switched to BRV 200 mg/day after discontinuing LEV due to such side effects; as well as the efficacy, safety and tolerability of BRV. No statistical hypothesis testing will be performed.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Brivaracetam
  • Levetiracetam
  • Epilepsy
  • Nonpsychotic behavior
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject with well-characterized Epilepsy according to the 1989 International League Against Epilepsy (ILAE) classification
  • Subject with Epilepsy who the investigator expects will benefit from Levetiracetam (LEV) but for whom the investigator has decided to discontinue due to nonpsychotic behavioral side effects following the introduction of LEV
  • Subject is currently receiving LEV at the recommended therapeutic dose (dose ranging from 1 g/day to 3 g/day)
  • Subject currently treated with minimum 2 and maximum 3 Anti-Epileptic Drugs (AEDs) including LEV. Vagal Nerve Stimulation (VNS) is allowed and will be counted as a concomitant AED
  • Female subjects without ( for at least 2 years, bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible. Female subjects with childbearing potential are eligible if they use a medically accepted method

Exclusion criteria

Exclusion Criteria:

  • Subject has a lifetime history of suicide attempt (including an actual, interrupted or aborted attempt), or has had suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Visit 1
  • Subject whose seizures could not be reliably counted on a regular basis due to their fast and repetitive occurrence (clusters or flurries)
  • Subject has history or presence of status epilepticus during the year preceding Visit 1 or during Baseline
  • Subject has history or presence of known psychogenic nonepileptic seizures
  • Subject has any clinical conditions (eg, bone marrow depression, chronic hepatic disease, and/or severe renal impairment) which impair reliable participation in the study or necessitate the use of medication not allowed by protocol
  • Subject is pregnant or lactating
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Brivaracetam

    The subjects will be treated with Brivaracetam (BRV) tablets 200 mg/day during 12 weeks: four 25 mg tablets, twice daily. Based on the Investigator's judgement, at any time, the dose can be decreased to BRV 150 mg/day, 100 mg/day, or 50 mg/day. Flexible dosing, can be up- and down-titrated as needed. At the end of the Treatment Period, the subject will either enter the N01372 long-term follow-up study or down-titrate during 4 weeks.

    Drug: Brivaracetam

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Who Achieved a Clinically Meaningful Reduction of Nonpsychotic Behavioral Side Effects Based on the Investigator's Overall Assessment From Study Entry to the End of the Treatment Period

    Nonpsychotic behavioral side effects include (but are not limited to) such symptoms as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, irritability, etc. The Investigator completed the assessment by answering the following: "Has there been a clinically meaningful reduction of nonpsychotic behavioral side effects since the start of BRV?" - Yes/No

    Time frame: From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit

Secondary outcomes

  1. Shift in the Maximum Intensity From Baseline to the End of the Treatment Period for Side Effects Primarily Associated With Discontinuation of Levetiracetam (LEV) as Determined by the Investigator

    Nonpsychotic behavioral side effects include (but are not limited to) such symptoms as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, irritability, etc.

    Time frame: From Baseline (maximum of 12 weeks prior to Study Entry at Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit

  2. Change From Study Entry in Nonpsychotic Behavioral Side Effects to the End of the Treatment Period/Early Discontinuation Visit, Measured by Means of the Investigator Global Evaluation of Nonpsychotic Behavioral Side Effects (I-GEBSE) Scale

    There are seven levels for the I-GEBSE: * Marked improvement * Moderate improvement * Slight improvement * No change * Slight worsening * Moderate worsening * Marked worsening

    Time frame: From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit

  3. Number of Subjects Who Have a Complete Abatement of Nonpsychotic Behavioral Side Effects for the Last Assessment During the Treatment Period, Based on the Investigator's Overall Assessment

    Nonpsychotic behavioral side effects include (but are not limited to) such symptoms as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, irritability, etc.

    Time frame: From Baseline (maximum of 12 weeks prior to Study Entry at Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit

  4. Number of Subjects Who Are Free From Nonpsychotic Behavioral Side Effects Over the Entire Treatment Period

    Nonpsychotic behavioral side effects (NBSE) include (but are not limited to) such symptoms as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, irritability, etc.

    Time frame: From Visit 2 (Week 0) to Visit 6 (Week 12)

  5. Incidence of Treatment Emergent Adverse Events During the Study Period

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A treatment emergent AE is any event that emerges during treatment having been absent pre-treatment, or worsens relative to the pre-treatment state.

    Time frame: From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit

  6. Withdrawal Due to an Adverse Event (AE) During the Study Period

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.

    Time frame: From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit

  7. Occurrence of Serious Adverse Events During the Study Period

    A serious adverse event is any untoward medical occurrences in a subject administered study treatment, whether or not the event is related to treatment, with at least one of the follow outcomes: death, life-threatening, initial inpatient hospitalization or prolongation of hospitalization, significant or persistent disability/incapacity, congenital anomaly/birth defect, or an important medical event that may jeopardize the subject and require a medical/surgical intervention.

    Time frame: From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit

  8. Partial Onset Seizure (POS) Frequency Over the Treatment Period for Subjects With Focal Epilepsy

    The POS frequency is standardized to a 28-day duration and changes in POS frequency are measured relative to the reported seizure counts for the 4 weeks prior to Visit 2 (Week 0). Partial seizures can be classified into one of the following three groups: * Simple partial seizures (IA) * Complex partial seizures (IB) * Partial seizures evolving to secondarily generalized seizures (IC)

    Time frame: From 4 weeks prior to Visit 2 (Week 0) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit

  9. Generalized Seizure Days Over the Treatment Period for Subjects With Idiopathic Generalized Epilepsy

    Generalized seizure days are standardized to a 28-day duration and changes in generalized seizure days are measured relative to the reported seizure counts for the 4 weeks prior to Visit 2 (Week 0). Generalized seizures (Type II) include the following seizure types: * Absence (IIA1) * Atypical absence (IIA2) * Myoclonic (IIB) * Clonic (IIC) * Tonic (IID) * Tonic-clonic (IIE) * Atonic (IIF) A specific effect of BRV on the occurrence of generalized seizures was not assessed.

    Time frame: From 4 weeks prior to Visit 2 (Week 0) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit

07

Results

Posted Aug 15, 2016

Participant flow

This study started to enroll subjects in July 2012. In Oct 2013, the Sponsor evaluated the study in light of the recruitment rate. Given the unanticipated lack of recruitment during the prior 8 weeks, a decision was made to stop recruitment as of 16 Oct 2013.

Participant flow — Overall Study
MilestoneBrivaracetam
Started29
Completed26
Not completed3
Withdrew: Lack of efficacy1
Withdrew: Sae, non-fatal1
Withdrew: Ae, non-serious non-fatal1

Outcome measures

PrimaryPercentage of Subjects Who Achieved a Clinically Meaningful Reduction of Nonpsychotic Behavioral Side Effects Based on the Investigator's Overall Assessment From Study Entry to the End of the Treatment Period

Nonpsychotic behavioral side effects include (but are not limited to) such symptoms as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, irritability, etc. The Investigator completed the assessment by answering the following: "Has there been a clinically meaningful reduction of nonpsychotic behavioral side effects since the start of BRV?" - Yes/No

Time frame:
From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Achieved a Clinically Meaningful Reduction of Nonpsychotic Behavioral Side Effects Based on the Investigator's Overall Assessment From Study Entry to the End of the Treatment Period
percentage of subjectsBrivaracetam
Percentage of Subjects Who Achieved a Clinically Meaningful Reduction of Nonpsychotic Behavioral Side Effects Based on the Investigator's Overall Assessment From Study Entry to the End of the Treatment Period93.1
SecondaryShift in the Maximum Intensity From Baseline to the End of the Treatment Period for Side Effects Primarily Associated With Discontinuation of Levetiracetam (LEV) as Determined by the Investigator

Nonpsychotic behavioral side effects include (but are not limited to) such symptoms as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, irritability, etc.

Time frame:
From Baseline (maximum of 12 weeks prior to Study Entry at Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
Reported as:
Number · subjects
Shift in the Maximum Intensity From Baseline to the End of the Treatment Period for Side Effects Primarily Associated With Discontinuation of Levetiracetam (LEV) as Determined by the Investigator
subjectsBrivaracetam
Improvement8
Unchanged2
Worsening0
Resolved19
SecondaryChange From Study Entry in Nonpsychotic Behavioral Side Effects to the End of the Treatment Period/Early Discontinuation Visit, Measured by Means of the Investigator Global Evaluation of Nonpsychotic Behavioral Side Effects (I-GEBSE) Scale

There are seven levels for the I-GEBSE: * Marked improvement * Moderate improvement * Slight improvement * No change * Slight worsening * Moderate worsening * Marked worsening

Time frame:
From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
Reported as:
Number · subjects
Change From Study Entry in Nonpsychotic Behavioral Side Effects to the End of the Treatment Period/Early Discontinuation Visit, Measured by Means of the Investigator Global Evaluation of Nonpsychotic Behavioral Side Effects (I-GEBSE) Scale
subjectsBrivaracetam
Marked improvement10
Moderate improvement10
Slight improvement4
No change2
Slight worsening1
Moderate worsening0
Marked worsening1
Missing1
SecondaryNumber of Subjects Who Have a Complete Abatement of Nonpsychotic Behavioral Side Effects for the Last Assessment During the Treatment Period, Based on the Investigator's Overall Assessment

Nonpsychotic behavioral side effects include (but are not limited to) such symptoms as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, irritability, etc.

Time frame:
From Baseline (maximum of 12 weeks prior to Study Entry at Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
Reported as:
Number · subjects
Number of Subjects Who Have a Complete Abatement of Nonpsychotic Behavioral Side Effects for the Last Assessment During the Treatment Period, Based on the Investigator's Overall Assessment
subjectsBrivaracetam
Number of Subjects Who Have a Complete Abatement of Nonpsychotic Behavioral Side Effects for the Last Assessment During the Treatment Period, Based on the Investigator's Overall Assessment18
SecondaryNumber of Subjects Who Are Free From Nonpsychotic Behavioral Side Effects Over the Entire Treatment Period

Nonpsychotic behavioral side effects (NBSE) include (but are not limited to) such symptoms as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, irritability, etc.

Time frame:
From Visit 2 (Week 0) to Visit 6 (Week 12)
Reported as:
Number · subjects
Number of Subjects Who Are Free From Nonpsychotic Behavioral Side Effects Over the Entire Treatment Period
subjectsBrivaracetam
Number of Subjects Who Are Free From Nonpsychotic Behavioral Side Effects Over the Entire Treatment Period3
SecondaryIncidence of Treatment Emergent Adverse Events During the Study Period

An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A treatment emergent AE is any event that emerges during treatment having been absent pre-treatment, or worsens relative to the pre-treatment state.

Time frame:
From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
Reported as:
Number · events
Incidence of Treatment Emergent Adverse Events During the Study Period
eventsBrivaracetam
Incidence of Treatment Emergent Adverse Events During the Study Period67
SecondaryWithdrawal Due to an Adverse Event (AE) During the Study Period

An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.

Time frame:
From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
Reported as:
Number · subjects
Withdrawal Due to an Adverse Event (AE) During the Study Period
subjectsBrivaracetam
Withdrawal Due to an Adverse Event (AE) During the Study Period2
SecondaryOccurrence of Serious Adverse Events During the Study Period

A serious adverse event is any untoward medical occurrences in a subject administered study treatment, whether or not the event is related to treatment, with at least one of the follow outcomes: death, life-threatening, initial inpatient hospitalization or prolongation of hospitalization, significant or persistent disability/incapacity, congenital anomaly/birth defect, or an important medical event that may jeopardize the subject and require a medical/surgical intervention.

Time frame:
From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
Reported as:
Number · events
Occurrence of Serious Adverse Events During the Study Period
eventsBrivaracetam
Occurrence of Serious Adverse Events During the Study Period1
SecondaryPartial Onset Seizure (POS) Frequency Over the Treatment Period for Subjects With Focal Epilepsy

The POS frequency is standardized to a 28-day duration and changes in POS frequency are measured relative to the reported seizure counts for the 4 weeks prior to Visit 2 (Week 0). Partial seizures can be classified into one of the following three groups: * Simple partial seizures (IA) * Complex partial seizures (IB) * Partial seizures evolving to secondarily generalized seizures (IC)

Time frame:
From 4 weeks prior to Visit 2 (Week 0) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
Reported as:
Median · partial onset seizures
Partial Onset Seizure (POS) Frequency Over the Treatment Period for Subjects With Focal Epilepsy
partial onset seizuresBrivaracetam
Partial Onset Seizure (POS) Frequency Over the Treatment Period for Subjects With Focal Epilepsy6.0 (2.2 to 17.7)
SecondaryGeneralized Seizure Days Over the Treatment Period for Subjects With Idiopathic Generalized Epilepsy

Generalized seizure days are standardized to a 28-day duration and changes in generalized seizure days are measured relative to the reported seizure counts for the 4 weeks prior to Visit 2 (Week 0). Generalized seizures (Type II) include the following seizure types: * Absence (IIA1) * Atypical absence (IIA2) * Myoclonic (IIB) * Clonic (IIC) * Tonic (IID) * Tonic-clonic (IIE) * Atonic (IIF) A specific effect of BRV on the occurrence of generalized seizures was not assessed.

Time frame:
From 4 weeks prior to Visit 2 (Week 0) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit

No measurements were reported for this outcome.

Adverse events

Collected over Adverse Events were collected from Screening Period (Week -1) over the 12-weeks Treatment Period until the Safety Visit (Week 15-18 + max 7 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brivaracetam—1/29 (3.4%)13/29 (44.8%)
Most frequent serious events
Most frequent serious events
EventBrivaracetam
Suicidal ideationPsychiatric disorders1/29
Suicide attemptPsychiatric disorders1/29
Most frequent other events
Most frequent other events
EventBrivaracetam
HeadacheNervous system disorders5/29
FatigueGeneral disorders3/29
Back painMusculoskeletal and connective tissue disorders3/29
NasopharyngitisInfections and infestations2/29
DizzinessNervous system disorders2/29
TremorNervous system disorders2/29
DepressionPsychiatric disorders2/29
InsomniaPsychiatric disorders2/29

Baseline characteristics

Baseline Characteristics refer to the Enrolled Set.

Age, Categorical
Age, Categorical(Participants)Brivaracetam
<=18 years0
Between 18 and 65 years29
>=65 years0
Age, Continuous
Age, Continuous(years)Brivaracetam
Mean35.8 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Brivaracetam
Female14
Male15
08

Study locations

12 sites
  • 103
    Little Rock, Arkansas, United States
  • 108
    Lexington, Kentucky, United States
  • 109
    New York, New York, United States
  • 106
    Akron, Ohio, United States
  • 110
    Dallas, Texas, United States
  • 102
    Salt Lake City, Utah, United States
  • 203
    Amiens, France
  • 201
    Paris, France
  • 303
    Bernau, Germany
  • 300
    Kehl-Kork, Germany
  • 502
    Sevilla, Spain
  • 603
    Salford, United Kingdom
09

References and documents

Publications

  • Yates SL, Fakhoury T, Liang W, Eckhardt K, Borghs S, D'Souza J. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015 Nov;52(Pt A):165-8. doi: 10.1016/j.yebeh.2015.09.005. Epub 2015 Sep 29. PubMed 26432008 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 2 years 9 months after primary completion. A results delay was requested in Dec 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2012
First posted
Jul 30, 2012
Start
Jul 2012
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results delay requested
Dec 20, 2013
Results first posted
Aug 15, 2016
Last update
Jul 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01653262
Lead sponsor
UCB Pharma SA
Responsible party
Sponsor
First posted
Jul 30, 2012
Start date
Jul 2012
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Aug 15, 2016
Last update
Jul 11, 2018

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion